At the healthcare conference, Moderna lowered expected 2025 revenue to the range of $1.5 billion to $2.5 billion -- down from ...
Cases of norovirus infections are surging, but coming up with a way to prevent them has proven to be a challenge.
Moderna Inc. (NYSE: MRNA) has revised its sales projections for 2025, lowering expectations due to sluggish demand for its ...
A replay of each webcast will be archived on Moderna's website for at least 30 days following the presentation. Moderna is a leader in the creation of the field of mRNA medicine. Through the ...
Achieved 2024 product sales of $3.0 to 3.1 billion (unaudited) and an ending cash balance of approximately $9.5 billion (unaudited) ...
Or so the industry wisdom goes. The go-to-market feat of Moderna—the COVID wunderkind that would capture almost $40 billion in sales over the course of a couple of years—was perhaps even more ...
But timestamps on the station’s website are posted in Pacific time, not Eastern. Text in the image falsely claims Moderna said the vaccine had a “107% efficacy” that lasts “three days ...
Moderna, a leader in mRNA medicine, developed one of the earliest COVID-19 vaccines, with Spikevax being its first commercial product. The company's mRNA platform enables the development of ...
Achieved 2024 product sales of $3.0 to 3.1 billion (unaudited) and an ending cash balance of approximately $9.5 billion (unaudited)Updates 2025 expected revenue range to $1.5 to 2.5 billionExpects to ...